T-knife Therapeutics logo

T-knife Therapeutics

T-knife uses a mouse platform to create human TCRs for cancer treatment without modification.

78 employees · est. 2018 · San Francisco, United States

VS
T-Therapeutics Ltd logo

T-Therapeutics Ltd

Making T-Cell Receptor Biologics a Reality

62 employees · est. 2022 · Cambridge, United Kingdom

T-knife Therapeutics is the older company (2018 vs 2022).

Side-by-Side Comparison

T-knife Therapeutics T-Therapeutics Ltd
Founded
2018 older 2022
Headquarters
San Francisco, United States Cambridge, United Kingdom
Employees
78 62
Industry
Not tracked yet Biotechnology, Health Care
Funding Stage
Series B Series A
Total Funding
$184.00M $48.00M
Funding Rounds
4 1
Services
Development of T Cell Therapies, Clinical Research and Trials, Biological Engineering Development of T cell receptor-based drugs, Proprietary OpTiMus platform, Cancer treatment research and development
Target Customers
Cancer Patients with Solid Tumors, Healthcare Providers, Oncologists Cancer patients, Healthcare professionals, Pharmaceutical companies, Investors interested in biotech
Taxonomy
TCR-T Cell Therapy, Human TCR Development, Cancer Treatment, HuTCR Mouse Platform, Tumor-Specific TCRs, Solid Tumors, Cancer Testis Antigens, Oncoviral Antigens, Tumor-Driving Neoantigens, Adoptive T Cell Therapy, Gene Therapy, Immuno-Oncology, Tumor Immunology, TCR Generation, TCR Characterization T-Cell Receptor Biologics, TCR Therapeutics, OpTiMus Platform, Humanized TCR Mouse, Antigen-specific TCRs, Mouse Genome Engineering, Biopharmaceutical Drug Development, Single Cell Genomics, Structural Biology, Research And Development, Therapeutic Innovation, University Spin-out, Academic Science Collaboration
Website
t-knife.com t-therapeutics.com
T-knife Therapeutics logo

About T-knife Therapeutics

T-knife Therapeutics is a biopharmaceutical innovator founded in 2018 in the United States. The company is at the forefront of developing transformative therapies to combat cancer through its proprietary technology. Central to its mission is a paradigm-shifting approach utilizing its HuTCR mouse pla...

T-Therapeutics Ltd logo

About T-Therapeutics Ltd

T-Therapeutics Ltd, with the slogan "Making T-Cell Receptor Biologics a Reality", is a promising startup in the Biotechnology and Health Care sectors, headquartered in the United Kingdom. Founded in 2022 as a spin-out from the University of Cambridge, it rides on the waves of cutting-edge academic s...

We will tell you when either one moves

BounceWatch watches T-knife Therapeutics and T-Therapeutics Ltd for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at T-knife Therapeutics and T-Therapeutics Ltd — by email.

Frequently Asked Questions

T-knife Therapeutics — T-knife uses a mouse platform to create human TCRs for cancer treatment without modification.. T-Therapeutics Ltd — Making T-Cell Receptor Biologics a Reality. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
T-knife Therapeutics has raised $184.00M while T-Therapeutics Ltd has raised $48.00M.
T-knife Therapeutics and T-Therapeutics Ltd operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare T-knife Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at T-knife Therapeutics on 15 Jun 2026, and T-Therapeutics Ltd on 25 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy